A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

Keyphrases

• Irinotecan 100%
• Metastatic Breast Cancer 100%
• Topoisomerase 100%
• Topotecan 75%
• Monotherapy 25%
• Anthracyclines 25%
• Biological Agents 25%
• Taxanes 25%
• Topoisomerase Inhibitors 25%
• Adverse Events 12%
• Hematologic 12%
• Combination Therapy 12%
• Clinical Trials 12%
• Response Rate 12%
• Nausea-vomiting 12%
• Diarrhea 12%
• Phase II Trial 12%
• Toxicity Profile 12%
• Neutropenia 12%
• Previously Treated 12%
• Dosing Schedule 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Irinotecan 100%
• Metastatic Breast Cancer 100%
• DNA Topoisomerase 100%
• Topotecan 75%
• Monotherapy 25%
• Anthracycline 25%
• Taxane 25%
• Adverse Event 12%
• Biological Marker 12%
• Combination Therapy 12%
• Clinical Trial 12%
• Nausea and Vomiting 12%
• Biological Product 12%
• Neutropenia 12%
• Diarrhea 12%
• Diseases 12%
• Phase III Trials 12%